
Lipocine LPCN
$ 2.46
-4.07%
Quarterly report 2025-Q3
added 11-06-2025
Lipocine DPO Ratio 2011-2026 | LPCN
Annual DPO Ratio Lipocine
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 59.8 | 57.8 | 37.9 | 19.8 | 11.1 | 14.7 | 7.22 | 73.2 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.2 | 7.22 | 35.2 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
55 | $ 325.52 | -2.36 % | $ 42.6 B | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 21.88 | 0.92 % | $ 1.02 B | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
1.83 K | - | -5.16 % | $ 5.39 M | ||
|
Akebia Therapeutics
AKBA
|
168 | $ 1.38 | -10.97 % | $ 355 M | ||
|
Aquestive Therapeutics
AQST
|
395 | $ 4.22 | -0.59 % | $ 451 M | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.88 | -2.85 % | $ 3.04 B | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.53 | 2.35 % | $ 407 M | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Caladrius Biosciences
CLBS
|
51.2 | - | -16.75 % | $ 25.8 M | ||
|
Clearside Biomedical
CLSD
|
1.67 K | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
4.06 K | $ 33.66 | -0.63 % | $ 2.24 B | ||
|
bluebird bio
BLUE
|
182 | - | - | $ 546 M | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B |